Caprylate salt intermediates are critical building blocks in pharmaceutical manufacturing, especially valued for their robustness in downstream synthesis steps and their regulatory acceptability in parenteral and oral formulations. Featuring a molecular weight of 172.26 g/mol and a molecular formula of C8H15NaO2, sodium caprylate (CAS 1984-06-1) typifies these compounds, widely employed as both an excipient and a process intermediate. The precise control of stereochemistry during the synthesis is essential for reproducibility and for meeting stringent pharmacopoeial standards, given the functional group specificity required for subsequent reactions in active pharmaceutical ingredient (API) development. At Technical Insights, we leverage advanced process validation protocols to ensure that each batch of caprylate salt intermediates not only meets but exceeds industry purity and yield benchmarks, achieving consistent supply to regulated markets worldwide.
Production of caprylate salt intermediates on an industrial scale entails a robust, well-characterized sequence of operations designed for high yield, efficiency, and repeatability under cGMP conditions. The process initiates by charging octanoic acid (caprylic acid) into a stainless steel reactor with deionized water as the solvent. Sodium hydroxide solution is introduced gradually, maintaining vigorous agitation and a temperature between 20°C and 25°C to control the exotherm. This neutralization typically proceeds over two hours, ensuring that all the acidic functionality is converted to its sodium salt while minimizing the risk of hydrolysis or undesired side reactions.
Once neutralization is complete, the reaction mass is allowed to equilibrate, after which the pH is precisely adjusted to a range of 7.0-7.5 using additional sodium hydroxide or hydrochloric acid, as necessary. The mixture is then cooled to between 0°C and 5°C to promote crystallization of the sodium caprylate. Crystallization is maintained for one to two hours, ensuring optimal crystal growth and phase separation. The resulting solid is filtered under reduced pressure and subjected to sequential washes with chilled deionized water to remove any unreacted starting materials and process impurities.
Following isolation, caprylate salt intermediates produced by this method typically achieve an isolated yield of 94% with a purity exceeding 99.5% as determined by HPLC analysis. The integrity of the product structure is confirmed by 1H NMR spectroscopy: 1H NMR (400 MHz, DMSO-d6) δ 0.85 (t, J = 7.0 Hz, 3H), 1.17–1.29 (m, 10H), 1.58 (qq, J = 7.5, 7.5 Hz, 2H), 2.18 (t, J = 7.2 Hz, 2H), corroborating the appropriate substitution pattern and chain length of the caprylate backbone.
Complying with current Good Manufacturing Practices is foundational in the production of pharmaceutical intermediates, especially caprylate salts. Each batch is accompanied by a comprehensive Certificate of Analysis, which includes detailed 1H NMR and FT-IR spectral data for structural verification. Quantitative purity assays are performed via HPLC, and residual organic solvents are assessed in accordance with ICH Q3C guidelines using gas chromatography. Elemental impurities are scrutinized using ICP-MS per ICH Q3D requirements, and residual water content is determined by Karl Fischer titration. This rigorous characterization ensures that the product meets or surpasses strict regulatory release criteria. In addition, Technical Insights maintains a Drug Master File (DMF) for sodium caprylate and related intermediates, facilitating seamless regulatory filings and global supply to innovator and generic pharmaceutical manufacturers.
Achieving exceptional purity in caprylate salt intermediates mandates a carefully managed crystallization and isolation sequence. After the initial neutralization and pH adjustment, crystallization is performed at low temperature, allowing optimal nucleation and growth of sodium caprylate crystals. The filtered product is washed repeatedly — typically three sequential rinses with ice-cold deionized water — to eliminate surface-adhered impurities and residual ions, thus ensuring compliance with pharmacopeial standards. Final drying is conducted under vacuum at 40°C and a pressure of less than 20 mbar for eight hours, resulting in a free-flowing white powder with minimal moisture and robust batch-to-batch consistency. For detailed information about sodium caprylate salt intermediates, including technical specifications, visit the product page on our company website.
In terms of technical attributes, caprylate salt intermediates display a molecular weight of 172.26 g/mol, a chemical formula of C8H15NaO2, and an appearance as a free-flowing white crystalline powder. Purity, as verified by HPLC, consistently exceeds 99.5%. Water content, measured via Karl Fischer titration, is maintained below 1.0%. Assays for residual solvents per ICH Q3C return results below 50 ppm for all relevant classes. Elemental impurities, analyzed in line with ICH Q3D, register below regulatory limits, and the melting range is typically between 245°C and 250°C. These specifications are systematically recorded and verified with each released batch.
Overall, the industrial-scale production of caprylate salt intermediates at Technical Insights is designed for reliability and regulatory integrity. Through carefully validated processes and rigorous analytical characterization, we ensure high yield, exceptional purity, and a secure, compliant supply chain for pharmaceutical customers globally. This commitment to quality and transparency supports efficient, safe drug development and manufacture across the sector.
Related Articles
